Programme integrates systems, software and chemistries under the ProteomeLab brand name and leverages the company's technological strengths in the development of new products for proteomics
Beckman Coulter announces ProteomeLab, a new initiative that brings the company's life sciences technologies together to address current challenges in proteomics.
This programme integrates systems, software and chemistries under the ProteomeLab brand name and leverages the company's technological strengths in the development of new products for proteomics.
The initial offering includes the ProteomeLab PF 2D protein fractionation system for automated two-dimensional resolution; the ProteomeLab PA-800 protein characterisation system for high-resolution protein characterisation; and the ProteomeLab DU 800 system for enzyme kinetic studies.
Over the coming months new products, specialised chemistry and modifications of existing systems will be announced to complement the ProteomeLab family.
"Since the term 'proteome' was first coined in the mid 1990s, an integrated field of study (proteomics) has emerged that involves the systematic large-scale identification, characterisation and quantification of all proteins involved in a biological pathway," explains Jeff Chapman, strategic marketing manager for Beckman Coulter. "The generation of such a comprehensive data set requires an integrated, multi-technology strategy encompassing cellular isolation, antigen identification, protein fractionation, protein characterisation, data evaluation and ultimately disease diagnosis.
"ProteomeLab, which springs from a systems biology approach, addresses the range of challenges, from tissues to targets."